Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration (original) (raw)

Abstract

Bortezomib (VELCADE) is a proteasome inhibitor, which has been recently used for the treatment of relapsed/refractory multiple myeloma (MM) with encouraging results. Tumour lysis syndrome (TLS) has been described during chemotherapy for many haematological malignancies, such as acute lymphoblastic leukaemia and high-grade lymphomas. TLS is very rare in MM with ten reported cases, including ~1% of patients receiving high-dose chemotherapy with stem cell support (ASCT). We report here a patient with refractory MM and deletion 13q, who had received more than four lines of previous treatment, including two ASCT, and had relapsed. The patient received bortezomib, as a single agent, at a dose of 1.3 mg/m2 twice per week for 2 weeks, in a 3-week cycle, and developed TLS after the second dose of cycle one. Bortezomib therapy, due to the rapidity of its action, may result in TLS in myeloma patients who have rapidly proliferative disease with a high tumour burden. Therefore, TLS should be looked for during the first cycle of bortezomib treatment and suitable precautions should be considered.

Access this article

Log in via an institution

Subscribe and save

• Get 10 units per month
• Download Article/Chapter or eBook
• 1 Unit = 1 Article or 1 Chapter
• Cancel anytime Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

• Cany L, Fitoussi O, Boiron JM, Marit G (2002) Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma. J Clin Oncol 20:2212
  CAS Google Scholar
• Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL (1980) Acute tumor lysis syndrome. A review of 37 patients with Burkitt’s lymphoma. Am J Med 68:486–491
  Article CAS PubMed Google Scholar
• Fassas AB, Desikan KR, Siegel D, Golper TA, Munshi NC, Barlogie B, Tricot G (1999) Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematol 105:938–941
  Article CAS PubMed Google Scholar
• Fleming DR, Doukas MA (1992) Acute tumor lysis syndrome in hematologic malignancies. Leuk Lymphoma 8:315–318
  CAS PubMed Google Scholar
• Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC (2003) Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22:8386–8393
  Article CAS PubMed Google Scholar
• Jagannath S, Durie BGM, Wolf J, Berliner A, Camacho E, Gabayan E, Irwin D, Lutzky J, McKinley M, Potts P, Noble-Kempin S, Davis B, Mazumder A, Crowley J, Jacobson J, Schenk D (2003) Bortezomib (VELCADETM, formerly PS-341) as first-line therapy in patients with multiple myeloma (MM). Blood 102:2650a [abstr]
  Google Scholar
• Jeha S (2001) Tumor lysis syndrome. Semin Hematol 38 [Suppl 10]:4–8
• Kane RC, Bross PF, Farrell AT, Pazdur R (2003) Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8:508–513
  PubMed Google Scholar
• Killick S, Mercieca J, Nandi A, Behrens J (1997) Fludarabine-induced tumour lysis in low-grade non-Hodgkin’s lymphoma. Clin Lab Haematol 19:79–80
  Article CAS PubMed Google Scholar
• Mehta J, Jakob C, Singhal S, Stadtmauer E, Richardson P, Vesole D, Boral AL, Esseltine DL, Sezer O (2003) Bortezomib causes tumor lysis syndrome in approximately 1% of patients with myeloma. Blood 102 [Suppl 2]:386b [abstr]
• Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99:14374–14379
  Article CAS PubMed Google Scholar
• Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617
  Article CAS PubMed Google Scholar
• van de Kerkhof JJ, Peters WG, Visser J, Creemers GJ (2001) Acute tumor lysis syndrome in a patient with multiple myeloma treated with dexamethasone monotherapy. Neth J Med 59:83–85
  Article PubMed Google Scholar

Download references

Author information

Authors and Affiliations

1. Department of Haematology, Faculty of Medicine Imperial College, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK
   Evangelos Terpos, Marianna Politou & Amin Rahemtulla

Authors

1. Evangelos Terpos
   You can also search for this author inPubMed Google Scholar
2. Marianna Politou
   You can also search for this author inPubMed Google Scholar
3. Amin Rahemtulla
   You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toAmin Rahemtulla.

Rights and permissions

About this article

Cite this article

Terpos, E., Politou, M. & Rahemtulla, A. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.J Cancer Res Clin Oncol 130, 623–625 (2004). https://doi.org/10.1007/s00432-004-0593-4

Download citation

• Received: 19 February 2004
• Accepted: 14 May 2004
• Published: 28 July 2004
• Issue Date: October 2004
• DOI: https://doi.org/10.1007/s00432-004-0593-4

Key words